Logo - International Journal of Pharmaceutical Compounding

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2

Author(s):  Higgins Doral (Neal) O, Prudom Melanie J, Summers Amy

Issue:  Sep/Oct 2021 - Volume 25, Number 5
View All Articles in Issue

Abstract:  Container-closure integrity provides assurance that compounded sterile preparation quality attributes are met throughout its shelf life. Since compounded sterile preparations lacking container-closure integrity are considered adulterated as per the Federal Food, Drug and Cosmetic Act and are therefore unsafe for patient use, compounders must be able to produce a well closed sealed vial. Furthermore, 503B outsourcing facilities must qualify the capping process as described by the proposed “Current Good Manufacturing Practice – Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug and Cosmetic Act Guidance for Industry.” This article is the second in a series describing vial crimping and capping equipment selection and the qualification necessary to create a well-closed sealed vial in a Current Good Manufacturing Practice environment to ensure patient safety and maintain compliance.

Related Keywords: Doral (Neal) O. Higgins, Melanie J. Prudom, MBA, Amy Summers, PharmD, BCSCP, container-closure integrity, container-closure system, U.S. Food, Drug and Cosmetic Act, vial sealing, compounded sterile preparations, capper devices, crimper devices, vial-capping qualification process, installation qualification, operational qualification, performance qualification, drug safety


Purchase this article for download in electronic PDF format from IJPC at for $35 at:

Search the entire IJPC archive by keyword, topic, or issue at: